Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Epublish 40 citations
PubMed: 35369871 DOI: 10.1186/s12916-022-02333-0
Global diversity of policy, coverage, and demand of COVID-19 vaccines: a descriptive study.
BMC Med 20(1):130
Authors: Zhiyuan Chen, Wen Zheng, Qianhui Wu, Xinghui Chen, Cheng Peng, Yuyang Tian, Ruijia Sun, Jiayi Dong, Minghan Wang, Xiaoyu Zhou, Zeyao Zhao, Guangjie Zhong, Xuemei Yan, Nuolan Liu, Feiran Hao, Sihong Zhao, Tingyu Zhuang, Juan Yang, Andrew S Azman, Hongjie Yu
Affiliations
- School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, 200032, China.
- Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
- Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
- School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, 200032, China.
- Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.
- Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
Abstract
BACKGROUND
Hundreds of millions of doses of coronavirus disease 2019 (COVID-19) vaccines have been administered globally, but progress on vaccination varies considerably between countries. We aimed to provide an overall picture of COVID-19 vaccination campaigns, including policy, coverage, and demand of COVID-19 vaccines.
METHODS
We conducted a descriptive study of vaccination policy and doses administered data obtained from multiple public sources as of 8 February 2022. We used these data to develop coverage indicators and explore associations of vaccine coverage with socioeconomic and healthcare-related factors. We estimated vaccine demand as numbers of doses required to complete vaccination of countries' target populations according to their national immunization program policies.
RESULTS
Messenger RNA and adenovirus vectored vaccines were the most commonly used COVID-19 vaccines in high-income countries, while adenovirus vectored vaccines were the most widely used vaccines worldwide (180 countries). One hundred ninety-two countries have authorized vaccines for the general public, with 40.1% (77/192) targeting individuals over 12 years and 32.3% (62/192) targeting those ≥ 5 years. Forty-eight and 151 countries have started additional-dose and booster-dose vaccination programs, respectively. Globally, there have been 162.1 doses administered per 100 individuals in target populations, with marked inter-region and inter-country heterogeneity. Completed vaccination series coverage ranged from 0.1% to more than 95.0% of country target populations, and numbers of doses administered per 100 individuals in target populations ranged from 0.2 to 308.6. Doses administered per 100 individuals in whole populations correlated with healthcare access and quality index (R = 0.59), socio-demographic index (R = 0.52), and gross domestic product per capita (R = 0.61). At least 6.4 billion doses will be required to complete interim vaccination programs-3.3 billion for primary immunization and 3.1 billion for additional/booster programs. Globally, 0.53 and 0.74 doses per individual in target populations are needed for primary immunization and additional/booster dose programs, respectively.
CONCLUSIONS
There is wide country-level disparity and inequity in COVID-19 vaccines rollout, suggesting large gaps in immunity, especially in low-income countries.
MeSH
Immunization, Vaccines, Immunization Programs, Covid-19 Vaccines, Adenoviridae, Income, Vaccination, Covid-19
Cited by
- COVID-19 Vaccine Booster Hesitancy among the Elderly in Malaysian Residential Care Homes: A Cross-Sectional Study in Klang Valley. Vaccines (Basel), 2024
- Changes in social mixing and attitudes and practices to precautionary measures in a maturing COVID-19 pandemic in six communities in Sudan: a qualitative study. BMC Public Health, 2024
- Determinants of COVID-19 cases and deaths in OECD countries. Z Gesundh Wiss, 2023
- A Scoping Review of Factors Affecting COVID-19 Vaccination Uptake and Deployment in Global Healthcare Systems. Vaccines (Basel), 2024
- A systemic evaluation of COVID-19 vaccination drives in LICs, LMICs, UMICs, and HICs: Preparedness for future pandemics. J Family Med Prim Care, 2025
- Barriers to COVID-19 vaccine acceptance to improve messages for vaccine uptake in indigenous populations in the central highlands of Guatemala: a participatory qualitative study. BMJ Open, 2023
- Factors associated with timely COVID-19 vaccination in a population-based cohort of patients with cancer. J Natl Cancer Inst, 2023
- Global border restrictions in 2020-2021: Adherence and the effectiveness in long-term COVID-19 epidemic control. Travel Med Infect Dis, 2023
- Evaluating geographic accessibility to COVID-19 vaccination across 54 countries/regions. BMJ Glob Health, 2025
- Economic evaluation of vaccination against COVID-19: A systematic review. Health Sci Rep, 2024
- Health Technology Assessment of Vaccines in Italy: History and Review of Applications. Vaccines (Basel), 2024
- Design and Analysis Heterogeneity in Observational Studies of COVID-19 Booster Effectiveness: A Review and Case Study. medRxiv, 2023
- Correlates of COVID-19 vaccination intentions and opinions about mandates among four groups of adults in South Africa with distinct vaccine intentions: evidence from a large national survey. BMC Public Health, 2023
- Effectiveness of containment strategies in preventing SARS-CoV-2 transmission. J Infect Public Health, 2023
- Assessing the transition of COVID-19 burden towards the young population while vaccines are rolled out in China. Emerg Microbes Infect, 2022
- Relative vaccine effectiveness of the booster dose of COVID-19 vaccine for preventing death in individuals with a primary regimen based on the BBIBP-CorV, ChAdOx1-S, or BNT162b2 vaccines during the Omicron wave in Peru: A nested case-control study using national population data. Vaccine, 2022
- Access to the COVID-19 Vaccine. Int J Environ Res Public Health, 2022
- Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults. EBioMedicine, 2023
- Design and analysis heterogeneity in observational studies of COVID-19 booster effectiveness: A review and case study. Sci Adv, 2023
- Does integration matter? an international cross-sectional study on the relationship between perceived public health and primary care integration and COVID-19 vaccination rates. PLoS One, 2025